The growth of this market is majorly driven by the launch of new products and favorable reimbursement scenario. However, the shift toward minimally invasive surgeries and adverse effect of hemostats are the major factors restraining the growth of this market.
Key questions addressed in the report:
# What are the growth opportunities in the hemostats and sealants market across major countries in Europe in the future?
# What are the key drivers and restraints in the hemostats and sealants market?
# What are the key brands in the hemostats and sealants market?
# Which are the key countries in the hemostats and sealants market?
# What are the most preferred brands amongst end users?
Download PDF@
Based on focused products, Tachosil is projected to register the highest growth during the forecast period
Based on focused products, the market is segmented into Tachosil, Lyostypt, Sangustop, Veriset, Avitene, and Hemopatch. Tachosil is expected to grow at the highest CAGR during the forecast period, mainly due to the increasing demand for this product among end users.
Germany commands the largest share of the market
Based on region, the hemostats and sealants (focused products) market is segmented into Germany, the UK, France, Italy, and Spain. Germany dominates the hemostats and sealants market due to its large patient population and the favorable reimbursement scenario for the usage of hemostats.
Hemostats help in controlling bleeding at the site of wound or performing various open surgeries. The different types of products used include thrombin-based hemostats, combination hemostats, oxidized regenerated cellulose-based hemostats, gelatin-based hemostats, and collagen-based hemostats. Of these, combination hemostats are anticipated to grow at the highest rate in Europe, as they reduce the risk of side-effects post-application
Read More@
The market for hemostats and sealants is anticipated to grow mainly due to the launch of the new products, M&A’s, and favorable reimbursement scenario in Europe. However, the increasing preference for minimally invasive surgeries and the reducing preference for the usage of hemostats while performing surgeries are expected to hinder the growth of this market during the forecast year. Leading players operating in this market are Ethicon (J&J), Baxter, Pfizer, Baxter, C. R. Bard, and B. Braun.
Focused brands for this study are Hemopatch (Baxter), Tachosil (Takeda), Veriset (Medtronic), Avitene (C. R. Bard), and Sangustop & Lyostypt (B Braun).
No comments:
Post a Comment